Carnegie Investment Counsel Increases Stock Holdings in Pfizer Inc. $PFE

Key Points

• Carnegie Investment Counsel increased its Pfizer stake by 252.9% in Q4, buying 110,759 shares to hold 154,550 shares worth about $3.85 million at quarter-end.
• Pfizer beat Q4 estimates with $0.66 EPS (vs. $0.57 est.) and $17.56 billion revenue (vs. $16.93 billion est.), though revenue was down 1.2% year-over-year and analysts expect ~2.95 EPS for the current fiscal year.
• Institutional investors own about 68.36% of Pfizer; the stock trades in the mid-$20s (opened at $26.91), has a market cap around $153 billion and an average Wall Street price target near $28.14 with a consensus rating of "Hold."

Carnegie Investment Counsel lifted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 252.9% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 154,550 shares of the biopharmaceutical company's stock after purchasing an additional 110,759 shares during the quarter. Carnegie Investment Counsel's holdings in Pfizer were worth $3,848,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. State Street Corp boosted its holdings in shares of Pfizer by 0.9% in the 3rd quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company's stock worth $7,620,747,000 after purchasing an additional 2,786,098 shares during the period. Northern Trust Corp boosted its holdings in shares of Pfizer by 1.4% in the 3rd quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company's stock worth $1,631,225,000 after purchasing an additional 869,175 shares during the period. Fisher Asset Management LLC boosted its holdings in shares of Pfizer by 1.9% in the 3rd quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company's stock worth $1,255,860,000 after purchasing an additional 897,786 shares during the period. Legal & General Group Plc lifted its stake in shares of Pfizer by 8.6% during the 3rd quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company's stock worth $1,063,565,000 after acquiring an additional 3,296,415 shares during the last quarter. Finally, Amundi lifted its stake in shares of Pfizer by 10.8% during the 3rd quarter. Amundi now owns 41,490,929 shares of the biopharmaceutical company's stock worth $1,096,380,000 after acquiring an additional 4,043,413 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Trading Down 1.2%

Shares of NYSE PFE opened at $26.91 on Friday. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The business has a fifty day simple moving average of $27.20 and a two-hundred day simple moving average of $25.94. The firm has a market cap of $152.99 billion, a PE ratio of 19.78 and a beta of 0.43. Pfizer Inc. has a twelve month low of $21.28 and a twelve month high of $28.75.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating analysts' consensus estimates of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.Pfizer's revenue was down 1.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.63 EPS. Analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Morgan Stanley raised its price target to $28 and kept an "equal weight" rating, implying modest upside and signaling some confidence in near-term fundamentals. Morgan Stanley raises PFE price target (Benzinga)
• Positive Sentiment: MarketWatch noted a recent intraday uptick (but continued underperformance versus the broader market), which can attract short-term buyers looking for mean-reversion after pullbacks. Pfizer Inc. stock rises Wednesday (MarketWatch)
• Neutral Sentiment: Zacks flagged Pfizer as a "trending" stock, meaning elevated retail/institutional attention — this can increase volatility but doesn’t by itself indicate direction. Pfizer is a trending stock (Zacks)
• Neutral Sentiment: Coverage pieces (Yahoo/MSN) are re-examining Q4 earnings, one-year performance and valuation after a strong one‑year gain; these narratives shape whether investors view PFE as fairly valued or still a buy. Is Pfizer Offering Value (Yahoo) Q4 earnings highs and lows (MSN)
• Neutral Sentiment: Pfizer announced its virtual Annual Meeting on April 23; routine corporate governance items can temper short-term trading but are unlikely to change fundamentals. Annual meeting webcast (BusinessWire)
• Neutral Sentiment: Industry research on the biopharmaceutical CXO market cites Pfizer among large players navigating outsourcing and supply-chain trends — a background macro theme that could help longer-term margins but is not an immediate catalyst. Biopharmaceutical CXO market report (Yahoo/GlobeNewswire)
• Negative Sentiment: Bank of America cut its price target to $26 and moved to "neutral," signaling downside risk and adding selling pressure from model-driven desks. Bank of America lowers PFE PT (Benzinga)
• Negative Sentiment: Zacks ran a comparative piece showing AbbVie (ABBV) pulling ahead on strong growth from Skyrizi and Rinvoq, underscoring competitive headwinds in immunology that could pressure Pfizer’s growth multiple. AbbVie vs Pfizer growth comparison (Zacks)
• Negative Sentiment: Coverage explaining why Pfizer tumbled earlier in the week highlights mixed near-term signals (analyst downgrades, rotation to other healthcare names), which can prolong weak sentiment even after small positive data points. Why Pfizer stock tumbled (Yahoo)

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on PFE. BMO Capital Markets reissued an "outperform" rating and set a $30.00 price target on shares of Pfizer in a research note on Monday, March 9th. Weiss Ratings reissued a "hold (c-)" rating on shares of Pfizer in a research note on Thursday, January 22nd. Cantor Fitzgerald reissued a "neutral" rating and set a $27.00 price target on shares of Pfizer in a research note on Wednesday, February 4th. Daiwa Securities Group lowered Pfizer from an "outperform" rating to a "neutral" rating and set a $27.00 price target for the company. in a research note on Thursday, February 12th. Finally, TD Cowen reissued a "hold" rating on shares of Pfizer in a research note on Tuesday, December 30th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have given a Hold rating and three have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $28.14.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.